Psychedelic Bulletin: Proliferation of Psilocybin-Related Drug Development; Biden-Harris Administration Aims to Reduce Barriers to Schedule I Research Post published:September 10, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: DEA Proposes Increase to Psilocybin Quota; Field Trip Launches KAP Co-Operative Program; MindMed Files DTx Patent Application Post published:September 3, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: California Decrim. Bill Put on Pause; MindMed Inks Real-World Evidence Collaboration Post published:August 27, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Beckley Psytech Raises $80m in Series B; Bright Minds Biosciences Reports Positive Preclinical Findings; Psychedelics DNA Test Called Into Question Post published:August 20, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Compass Pathways Secures 5th Patent; atai to Develop Salvinorin A Post published:August 13, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: UK Patent Examiner Questions Compass Patent; Canadians Overwhelmingly Support Psilocybin Policy Reform; No Data Protection for Spravato in Canada Post published:August 6, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: MindMed Initiates DMT Trial; COMPASS Appoints CMO; Field Trip Lists on NASDAQ Post published:July 30, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Field Trip Set to List on Nasdaq; Cybin to List on NYSE American Post published:July 24, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Third Psychedelics ETF Expected to Launch; Tracking Psychedelic Drug Policy Reform; One Direction for atai Post published:July 16, 2021 Post category:Psychedelic Bulletin
Psychedelic Bulletin: Compass Announces New Collaboration; MindMed Partners with Real-World Data Provider; Yale Researchers Show Psilocybin Increases Nueronal Connections Post published:July 9, 2021 Post category:Psychedelic Bulletin